New data reveal that Ultibro (glycopyrronium bromide/ indacaterol) was superior to Seretide (salmeterol/fluticasone) in reducing flare ups in patients with moderate ...
The generic drug, montelukast should be offered to people ahead of combination inhalers such as GlaxoSmithKline's Seretide, in a bid to save the NHS millions of pounds, according to draft guidance ...
If Novartis wants to be a respiratory giant in Europe, it’s going to have to weasel market share away from GlaxoSmithKline. Now it has some new data it’s hoping can help on that front. Sunday, the New ...
Introduction: The incidence of asthma exacerbations in patients receiving salmeterol/fluticasone propionate (Seretide™ or Advair ®) is low. However, when asthma control deteriorates, clinicians may ...
Novartis’ Ultibro Breezhaler is more effective in patients at risk of chronic obstructive pulmonary disease (COPD) flare-ups than GlaxoSmithKline’s rival drug, Seretide, according to new data. The ...
Seretide/Advair is GSK’s best-selling drug, and the line was extended in 2003 when the European Union approved the higher-dose 500 Accuhaler for the symptomatic treatment of severe COPD, i.e., ...
GlaxoSmithKline said yesterday its combination asthma drug Seretide had become the first drug to reduce the risk of death in patients with chronic obstructive pulmonary disease (COPD). GlaxoSmithKline ...
LONDON, July 9 (Reuters) - GlaxoSmithKline Plc has won a licence extension in Europe for Seretide, allowing its top-selling inhaler product to be used in a wider population of patients with the lung ...
This study has demonstrated that doubling the dose of Seretide™ administered via the Diskus™ inhaler over a short period is safe and well tolerated. Whilst this is not a recommended treatment approach ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results